AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10853111 — intervention group
Group type: EXPERIMENTAL
Intervention: Last visit carried forward analysis for VNS
Number of subjects: 199
Study 10853111 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events and physiological variables monitoring
Number of subjects: 199
Study 8543520 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent- and child-administered structured DSM-III-R DISC interviews
Number of subjects: 294
Study 8543520 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' and children's symptom checklist ratings
Number of subjects: 294
Study 8543520 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' ratings of their own symptoms
Number of subjects: 294
Study 2407889 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone membranes
Number of subjects: 0
Study 2407889 — intervention group
Group type: EXPERIMENTAL
Intervention: DEAE-substituted cellulose membranes
Number of subjects: 0
Study 2407889 — intervention group
Group type: COMPARATOR
Intervention: Cellulose membranes
Number of subjects: 0
Study 2407889 — intervention group
Group type: EXPERIMENTAL
Intervention: All membranes
Number of subjects: 0
Study 7413152 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 264
Study 7413152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 7413152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoid macular edema patients
Number of subjects: 264
Study 7413152 — intervention group
Group type: EXPERIMENTAL
Intervention: Other patients (without cystoid macular edema)
Number of subjects: 264
Study 7413152 — intervention group
Group type: COMPARATOR
Intervention: Control group (unilaterally aphakic eyes)
Number of subjects: 264
Study 30566363 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (2.5 × 10^9 CFU/g) containing 9 bacterial strains (Ecologic Barrier)
Number of subjects: 41
Study 30566363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 41
Study 29737292 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 29737292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 29737292 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, likely placebo or standard treatment)
Number of subjects: 0
Study 26474430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150-300 mg twice a day)
Number of subjects: 64
Study 26474430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 26474430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 64
Study 23388562 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel poliglumex (PPX) 50 mg/m/wk with temozolomide 75 mg/m and radiation 2.0 Gy, 5 d/wk for a total dose of 60 Gy
Number of subjects: 25
Study 23388562 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide/radiation
Number of subjects: 25
Study 22378262 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis (Vyndaqel; Pfizer)
Number of subjects: 0
Study 19496531 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic (mouse) gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Number of subjects: 19
Study 19496531 — intervention group
Group type: COMPARATOR
Intervention: Human gp100 plasmid DNA injected intramuscularly at dosages of 100, 500, or 1,500 microg every three weeks for three doses.
Number of subjects: 19
Study 19496531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (xenogeneic and human gp100)
Number of subjects: 19
Study 17218661 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-patellar tendon-bone
Number of subjects: 99
Study 17218661 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple-strand semitendinosus/gracilis
Number of subjects: 99
Study 17218661 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 99
Study 15831193 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention trial
Number of subjects: 8
Study 15831193 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation research
Number of subjects: 8
Study 15831193 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome data-monitoring committee
Number of subjects: 8
Study 11320362 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged strenuous exercise (100-km ultramarathon)
Number of subjects: 10
Study 9230234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (5 mg)
Number of subjects: 18
Study 9230234 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg b.i.d.) with budesonide (800 microg b.i.d.)
Number of subjects: 18
Study 9230234 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg b.i.d.) with placebo
Number of subjects: 18
Study 8121125 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (165 mg/day)
Number of subjects: 51
Study 8121125 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1000 U/h)
Number of subjects: 51
Study 3478465 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice containing 0.1% fluoride
Number of subjects: 87
Study 3478465 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% citrate buffered dentifrice in a pluronic gel
Number of subjects: 87
Study 3478465 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.1% fluoride and 2% citrate buffer in a pluronic gel
Number of subjects: 87
Study 3478465 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 87
Study 30482616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tie over method
Number of subjects: 0
Study 30482616 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin stapler fixation
Number of subjects: 0
Study 30482616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue fixation
Number of subjects: 0
Study 27247448 — intervention group
Group type: EXPERIMENTAL
Intervention: Shielding drape
Number of subjects: 0
Study 27247448 — intervention group
Group type: COMPARATOR
Intervention: No shielding drape (control)
Number of subjects: 0
Study 25856785 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB + Hydrochlorothiazide (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Number of subjects: 0
Study 25856785 — intervention group
Group type: COMPARATOR
Intervention: ARB + Amlodipine (ARB + C)
Number of subjects: 0
Study 23350826 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based treatment programme (124 women)
Number of subjects: 250
Study 23350826 — intervention group
Group type: COMPARATOR
Intervention: Postal treatment programme (126 women)
Number of subjects: 250
Study 21295409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin/pyrantel pamoate chewable tablets
Number of subjects: 44
Study 21295409 — intervention group
Group type: EXPERIMENTAL
Intervention: Milbemycin oxime flavored tablets
Number of subjects: 44
Study 21295409 — intervention group
Group type: EXPERIMENTAL
Intervention: Selamectin topical solution
Number of subjects: 44
Study 21295409 — intervention group
Group type: COMPARATOR
Intervention: Imidacloprid/moxidectin topical solution
Number of subjects: 44
Study 21295409 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 44
Study 19826203 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape of the dose distribution (measured by lateral extent)
Number of subjects: 0
Study 19826203 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape of the dose distribution (measured by longitudinal extent)
Number of subjects: 0
Study 19826203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-surface histogram (DSH)
Number of subjects: 0
Study 19826203 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape of the dose distribution
Number of subjects: 0
Study 16399182 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffer implants (rigidity 1.8)
Number of subjects: 20
Study 16399182 — intervention group
Group type: COMPARATOR
Intervention: Regular implants (rigidity 1.0)
Number of subjects: 20
Study 15565453 — intervention group
Group type: EXPERIMENTAL
Intervention: Administered dose of 0.001 Sv
Number of subjects: 0
Study 11380543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-in-water (o/w) cream applied 2x/day for 14 days in ICD study
Number of subjects: 0
Study 11380543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-in-water (o/w) cream applied 2x/day for 4 consecutive days in ACD study
Number of subjects: 0
Study 8820892 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage treatment
Number of subjects: 10
Study 8820892 — intervention group
Group type: COMPARATOR
Intervention: Control (supine rest)
Number of subjects: 10
Study 1526413 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol for primary prevention of first bleeding in esophageal varices
Number of subjects: 109
Study 3899947 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal vaccine
Number of subjects: 405
Study 31026125 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-related knowledge, attitudes, and practices (KAP) intervention; specific details on dosage and duration not available.
Number of subjects: 0
Study 31026125 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to lower salt intake; specific details on dosage and duration not available.
Number of subjects: 0
Study 31026125 — intervention group
Group type: EXPERIMENTAL
Intervention: Checking salt/sodium labels in food; specific details on dosage and duration not available.
Number of subjects: 0
Study 31026125 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding extra salt to food at the table; specific details on dosage and duration not available.
Number of subjects: 0
Study 31026125 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting high amounts of salt consumption; specific details on dosage and duration not available.
Number of subjects: 0
Study 29412368 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial myofunctional therapy (OMT)
Number of subjects: 48
Study 29412368 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal occlusion)
Number of subjects: 48
Study 29412368 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (UTG)
Number of subjects: 48
Study 26946214 — intervention group
Group type: EXPERIMENTAL
Intervention: High axial force stent (WallFlex™)
Number of subjects: 0
Study 26946214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low axial force stent (Niti‐S™)
Number of subjects: 0
Study 26946214 — intervention group
Group type: COMPARATOR
Intervention: Comparison between W-group and N-group
Number of subjects: 0
Study 23868613 — intervention group
Group type: COMPARATOR
Intervention: Mammography intervention (details not specified)
Number of subjects: 704
Study 23070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed lactated Ringer's solution
Number of subjects: 60
Study 23070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hydroxyethyl starch solution (6% hydroxyethyl starch solution 130/0.4)
Number of subjects: 60
Study 23070341 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive lactated Ringer's solution
Number of subjects: 60
Study 20598806 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief injunctive norms manipulation
Number of subjects: 265
Study 20598806 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 265
Study 18980664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway (intervention group)
Number of subjects: 476
Study 18980664 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 476
Study 15812751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin chemotherapy (301 ± 52 mg/m²)
Number of subjects: 51
Study 15812751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin chemotherapy
Number of subjects: 51
Study 15812751 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SOD levels
Number of subjects: 51
Study 12454520 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (alpha‐tocopherol and ascorbate)
Number of subjects: 595
Study 12454520 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 595
Study 10352369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized acupuncture treatment
Number of subjects: 10
Study 10352369 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 10
Study 8547856 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 10 mg/kg
Number of subjects: 8
Study 8547856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (Trp) 1.2 g
Number of subjects: 8
Study 8547856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Caffeine and Tryptophan (CAF+Trp)
Number of subjects: 8
Study 8547856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study 1493533 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressing technique using cream (without silicone oil)
Number of subjects: 31
Study 1493533 — intervention group
Group type: COMPARATOR
Intervention: Vaseline (control)
Number of subjects: 31
Study 3991916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.6 g daily) for 24 h before and during the starvation period
Number of subjects: 20
Study 3991916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3991916 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine and Placebo
Number of subjects: 20
Study 30120003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cliradex® eyelid cleanser
Number of subjects: 10
Study 30120003 — intervention group
Group type: COMPARATOR
Intervention: 50% tea tree oil
Number of subjects: 10
Study 30120003 — intervention group
Group type: COMPARATOR
Intervention: Oust™ Demodex® cleanser
Number of subjects: 10
Study 30120003 — intervention group
Group type: COMPARATOR
Intervention: Blephadex™ eyelid foam
Number of subjects: 10
Study 30120003 — intervention group
Group type: COMPARATOR
Intervention: TheraTears® SteriLid® eyelid cleanser
Number of subjects: 10
Study 30120003 — intervention group
Group type: COMPARATOR
Intervention: Undiluted terpinen-4-ol
Number of subjects: 10
Study 30120003 — intervention group
Group type: COMPARATOR
Intervention: Linalool
Number of subjects: 10
Study 30120003 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 10
Study 29129441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (35 cycles)
Number of subjects: 305
Study 29129441 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator-choice platinum-doublet chemotherapy, 4-6 cycles)
Number of subjects: 305
Study 29129441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 305
Study 29129441 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 305
Study 23640810 — intervention group
Group type: EXPERIMENTAL
Intervention: Free anterolateral thigh perforator flap surgery
Number of subjects: 121
Study 23640810 — intervention group
Group type: COMPARATOR
Intervention: Radial forearm free flap surgery
Number of subjects: 121
Study 21233607 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyglucose positron emission tomography (FDG‐PET)
Number of subjects: 100
Study 19250084 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention
Number of subjects: 360
Study 19250084 — intervention group
Group type: COMPARATOR
Intervention: Primary prevention
Number of subjects: 360
Study 17253155 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirming feedback (information suggesting identification was correct)
Number of subjects: 0
Study 17253155 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicion manipulation (reasons to entertain suspicion regarding the motives of the lineup administrator)
Number of subjects: 0
Study 17253155 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence prophylactic effect (tested both immediately and after a one-week retention interval)
Number of subjects: 0
Study 17253155 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspicion manipulation
Number of subjects: 0
Study 15476516 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS-O (controlled-release oxybutynin)
Number of subjects: 105
Study 15476516 — intervention group
Group type: COMPARATOR
Intervention: IR-O (immediate-release oxybutynin)
Number of subjects: 105
Study 11411666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients with emotional support
Number of subjects: 431
Study 11411666 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer patients with partners
Number of subjects: 431
Study 11411666 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected men
Number of subjects: 431
Study 9148005 — intervention group
Group type: EXPERIMENTAL
Intervention: IMx CORE‐M assay
Number of subjects: 140
Study 9148005 — intervention group
Group type: EXPERIMENTAL
Intervention: IMx CORE‐M index value
Number of subjects: 140
Study 8375632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical administration of 1 mg oestriol
Number of subjects: 21
Study 8375632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3781503 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental residential program providing 24-hour care
Number of subjects: 0
Study 3781503 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care (Control)
Number of subjects: 0
Study 28464312 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 569
Study 28464312 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tension-free vaginal tape (TVT-O)
Number of subjects: 569
Study 27678290 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake above median levels (mean intake = 261mg)
Number of subjects: 6467
Study 27678290 — intervention group
Group type: COMPARATOR
Intervention: Caffeine intake below median levels (mean intake = 64mg)
Number of subjects: 6467
Study 24762110 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplementation (1000 mg daily, 5 d/wk for 1 year)
Number of subjects: 80
Study 24762110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22467284 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-shifting pure tone treatment
Number of subjects: 22
Study 22467284 — intervention group
Group type: COMPARATOR
Intervention: Pure tone treatment without phase shifting
Number of subjects: 22
Study 20663131 — intervention group
Group type: EXPERIMENTAL
Intervention: Arctic Front(R) catheter
Number of subjects: 108
Study 20663131 — intervention group
Group type: EXPERIMENTAL
Intervention: HD Mesh Ablator(R) catheter
Number of subjects: 108
Study 20663131 — intervention group
Group type: COMPARATOR
Intervention: Brain MRI, neuro(psycho)logical tests, and reveal recorder for AF detection
Number of subjects: 108
Study 18709309 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted broadband UVB phototherapy
Number of subjects: 10
Study 18709309 — intervention group
Group type: COMPARATOR
Intervention: Targeted NB-UVB phototherapy
Number of subjects: 10
Study 16124432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.2 mg/kg for 2 days
Number of subjects: 29
Study 16124432 — intervention group
Group type: COMPARATOR
Intervention: Albendazole 400 mg twice daily for 21 days
Number of subjects: 29
Study 16124432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 29
Study 16124432 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 29
Study 12610803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate therapy
Number of subjects: 40
Study 12610803 — intervention group
Group type: COMPARATOR
Intervention: Antirheumatic therapy alone (control)
Number of subjects: 40
Study 10501887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine-N-butylbromide (HB) 20 mg intraarterially
Number of subjects: 36
Study 10501887 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 36
Study 8943590 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 10 micrograms.ml‐1
Number of subjects: 60
Study 8943590 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with diamorphine 125 micrograms.ml‐1
Number of subjects: 60
Study 8943590 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 2.5 mg.ml‐1
Number of subjects: 60
Study 1683277 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexetimide
Number of subjects: 261
Study 1683277 — intervention group
Group type: COMPARATOR
Intervention: Artane
Number of subjects: 261
Study 7034583 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (0.15 mg)
Number of subjects: 50
Study 7034583 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine (5 mg)
Number of subjects: 50
Study 30630778 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid (100 mg twice daily for 2 months followed by 200 mg once daily for 4 months)
Number of subjects: 511
Study 30630778 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same regimen as delamanid)
Number of subjects: 511
Study 30630778 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid
Number of subjects: 511
Study 30630778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 511
Study 27170671 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anodal electrode on the rIFC, cathodal on the neck)
Number of subjects: 31
Study 27170671 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) tDCS
Number of subjects: 31
Study 25445201 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500mg bid)
Number of subjects: 30
Study 25445201 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (150mg qid)
Number of subjects: 30
Study 25445201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24179298 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 227
Study 24179298 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (ED)
Number of subjects: 227
Study 24179298 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 227
Study 21852264 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 34136
Study 21852264 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further contact)
Number of subjects: 34136